Home Cart Sign in  
Chemical Structure| 60186-89-2 Chemical Structure| 60186-89-2

Structure of 60186-89-2

Chemical Structure| 60186-89-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 60186-89-2 ]

CAS No. :60186-89-2
Formula : C6H7BrN2O2
M.W : 219.04
SMILES Code : COC1=CC(Br)=NC(OC)=N1
MDL No. :MFCD07787454
InChI Key :BFHOSMVQVHFCSK-UHFFFAOYSA-N
Pubchem ID :11287431

Safety of [ 60186-89-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 60186-89-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.33
Num. rotatable bonds 2
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 42.72
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

44.24 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.41
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.84
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.26
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.68
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.54
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.54

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.63
Solubility 0.515 mg/ml ; 0.00235 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.39
Solubility 0.893 mg/ml ; 0.00408 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.77
Solubility 0.375 mg/ml ; 0.00171 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.33 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.3

Application In Synthesis of [ 60186-89-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 60186-89-2 ]

[ 60186-89-2 ] Synthesis Path-Downstream   1~54

  • 1
  • [ 2314-97-8 ]
  • [ 60186-89-2 ]
  • [ 76513-87-6 ]
  • 4
  • [ 52517-92-7 ]
  • [ 60186-89-2 ]
  • [ 299966-38-4 ]
  • 5
  • [ 107428-20-6 ]
  • [ 60186-89-2 ]
  • (+/-)-3-allyl-5-[(Z)-(2,6-dimethoxy-4-pyrimidinyl)methylene]dihydro-2(3H)-furanone [ No CAS ]
  • 6
  • [ 60186-89-2 ]
  • [ 299966-60-2 ]
  • [ 299966-61-3 ]
  • 9
  • [ 946572-98-1 ]
  • [ 60186-89-2 ]
  • [ 946572-99-2 ]
  • 10
  • [ 959434-63-0 ]
  • [ 60186-89-2 ]
  • C27H39F2N5O6 [ No CAS ]
  • 11
  • [ 60186-89-2 ]
  • [ 946573-00-8 ]
  • 12
  • [ 60186-89-2 ]
  • C40H43N5O8 [ No CAS ]
  • 21
  • [ 60186-89-2 ]
  • (1'R,2'R)-2,6-dimethoxy-4-(2'-dibenzylamino-1'-hydroxy-4'-trityloxybutyl)pyrimidine [ No CAS ]
  • 22
  • [ 60186-89-2 ]
  • (2aS,3R,4S,5aS,7R)-7-[(S)-(tert-Butyl-dimethyl-silanyloxy)-(2,6-dimethoxy-pyrimidin-4-yl)-methyl]-3-methyl-4-triethylsilanyloxy-2,2a,3,4,5,5a,6,7-octahydro-1H-1,8,8b-triaza-acenaphthylene [ No CAS ]
  • 23
  • [ 60186-89-2 ]
  • [ 434309-02-1 ]
  • 24
  • [ 60186-89-2 ]
  • [ 434309-04-3 ]
  • 26
  • [ 60186-89-2 ]
  • (3R,4aS,6S,7R,8S)-8-Azidomethyl-3-[(S)-(tert-butyl-dimethyl-silanyloxy)-(2,6-dimethoxy-pyrimidin-4-yl)-methyl]-1-methoxy-7-methyl-6-triethylsilanyloxy-4,4a,5,6,7,8-hexahydro-3H-pyrido[1,2-c]pyrimidine [ No CAS ]
  • 27
  • [ 60186-89-2 ]
  • [(1R,2S)-1-[(1S,4R,5R,6S)-6-(4-Bromo-benzyloxymethyl)-5-methyl-7-oxa-1-aza-bicyclo[2.2.1]hept-2-ylmethyl]-2-(tert-butyl-dimethyl-silanyloxy)-2-(2,6-dimethoxy-pyrimidin-4-yl)-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • 30
  • [ 60186-89-2 ]
  • (4R,5S)-4-Dibenzylamino-5-(2,6-dimethoxy-pyrimidin-4-yl)-dihydro-furan-2-one [ No CAS ]
  • 31
  • [ 60186-89-2 ]
  • [ 812646-14-3 ]
  • 32
  • [ 60186-89-2 ]
  • (3R,4aS,6S,7R,8S)-8-Aminomethyl-3-[(S)-(tert-butyl-dimethyl-silanyloxy)-(2,6-dimethoxy-pyrimidin-4-yl)-methyl]-6-hydroxy-7-methyl-octahydro-pyrido[1,2-c]pyrimidin-1-one [ No CAS ]
  • 33
  • [ 60186-89-2 ]
  • (3R,4aS,7R,8S)-8-(4-Bromo-benzyloxymethyl)-3-[(S)-(tert-butyl-dimethyl-silanyloxy)-(2,6-dimethoxy-pyrimidin-4-yl)-methyl]-6-hydroxy-7-methyl-octahydro-pyrido[1,2-c]pyrimidin-1-one [ No CAS ]
  • 34
  • [ 60186-89-2 ]
  • [(1R,2S)-1-[(1S,2S,4R,5R,6S)-6-(4-Bromo-benzyloxymethyl)-5-methyl-7-oxa-1-aza-bicyclo[2.2.1]hept-2-ylmethyl]-2-(tert-butyl-dimethyl-silanyloxy)-2-(2,6-dimethoxy-pyrimidin-4-yl)-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • 35
  • [ 60186-89-2 ]
  • [(1R,2S)-1-[(2S,5R,6S)-6-(4-Bromo-benzyloxymethyl)-4-hydroxy-5-methyl-piperidin-2-ylmethyl]-2-(tert-butyl-dimethyl-silanyloxy)-2-(2,6-dimethoxy-pyrimidin-4-yl)-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • 36
  • [ 60186-89-2 ]
  • (2S,3R)-6-[(2R,3S)-2-Amino-3-(tert-butyl-dimethyl-silanyloxy)-3-(2,6-dimethoxy-pyrimidin-4-yl)-propyl]-2-(4-bromo-benzyloxymethyl)-3-methyl-piperidin-4-ol [ No CAS ]
  • 37
  • [ 60186-89-2 ]
  • [(1R,2S)-1-[(5R,6S)-6-(4-Bromo-benzyloxymethyl)-5-methyl-7-oxa-1-aza-bicyclo[2.2.1]hept-2-ylmethyl]-2-(tert-butyl-dimethyl-silanyloxy)-2-(2,6-dimethoxy-pyrimidin-4-yl)-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • 38
  • [ 60186-89-2 ]
  • [(1R,2S)-1-[(5R,6S)-6-(4-Bromo-benzyloxymethyl)-4-hydroxy-5-methyl-piperidin-2-ylmethyl]-2-(tert-butyl-dimethyl-silanyloxy)-2-(2,6-dimethoxy-pyrimidin-4-yl)-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • 39
  • [ 60186-89-2 ]
  • (+/-)-4-[(Z)-(2,6-dimethoxy-4-pyrimidinyl)methylene]tetrahydro-6-propyl-2(1H)-pyrimidinone [ No CAS ]
  • 40
  • [ 60186-89-2 ]
  • (+/-)-(4R,6R)-4-[(2,6-dimethoxy-4-pyrimidinyl)methyl]tetrahydro-6-propyl-2(1H)-pyrimidinone [ No CAS ]
  • 41
  • [ 60186-89-2 ]
  • [ 299966-63-5 ]
  • 42
  • [ 60186-89-2 ]
  • (+/-)-(4R,6R)-4-allyl-6-[(R)-(2,6-dimethoxy-4-pyrimidinyl)hydroxymethyl]tetrahydro-2(1H)-pyrimidinone [ No CAS ]
  • 43
  • [ 60186-89-2 ]
  • (+/-)-(4R,6R)-4-allyl-6-[(S)-(2,6-dimethoxy-4-pyrimidinyl)hydroxymethyl]tetrahydro-2(1H)-pyrimidinone [ No CAS ]
  • 44
  • [ 60186-89-2 ]
  • [ 299966-69-1 ]
  • 45
  • [ 60186-89-2 ]
  • 4-Nitro-benzoic acid (R)-((4S,6S)-6-allyl-2-oxo-hexahydro-pyrimidin-4-yl)-(2,6-dimethoxy-pyrimidin-4-yl)-methyl ester [ No CAS ]
  • 46
  • [ 696-62-8 ]
  • [ 60186-89-2 ]
  • [ 1233493-56-5 ]
  • 47
  • [ 51934-41-9 ]
  • [ 60186-89-2 ]
  • [ 1233493-52-1 ]
  • 48
  • [ 98-86-2 ]
  • [ 60186-89-2 ]
  • [ 1236194-05-0 ]
  • 52
  • [ 383-63-1 ]
  • [ 60186-89-2 ]
  • 1-(2,6-dimethoxypyrimidin-4-yl)-2,2,2-trifluoroethane-1,1-diol [ No CAS ]
YieldReaction ConditionsOperation in experiment
56% Into a 1-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed <strong>[60186-89-2]4-bromo-2,6-dimethoxypyrimidine</strong> (23 g, 105.01 mmol, 1 equiv), tetrahydrofuran (250 mL), Diethyl ether (250 mL). And n-BuLi(2.5M) (46.2 mg, 0.72 mmol, 1.10 equiv) was added dropwise at -78 C. After stirred for 5 min at -78 C, ethyl 2,2,2-trifluoroacetate (16.4 g, 115.43 mmol, 1.10 equiv) was added dropwise. After stirred for 30 min at -78 C, the resulting solution was stirred for overnight at RT. The reaction was then quenched by the addition of 200 mL of saturated NH4CI. Sodium carbonate was employed to adjust the pH to 8. The resulting solution was diluted with 1 L of EA. The resulting mixture was washed with 3x500 mL of brine. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 : 100- 1 : 10). The collected fractions were combined and concentrated under vacuum. This resulted in 15 g (56%) of the title compound as an off-white solid. Analytical Data: LC-MS: (ES, m/z): RT = 0.739 min, LCMS 32: m/z = 255 [M+l].
To a solution of <strong>[60186-89-2]4-bromo-2,6-dimethoxy-pyrimidine</strong> (6.80 g, 27.94 mmol) in THF (190 mL) and diethylether (190 mL) n-butyllithium (in hexane/THF, 2.01 g, 30.74 mmol) is added dropwise with stirring at -78 C. After 4 min ethyl trifluoroacetate (4.46 g, 30.74 mmol) in THF (50 mL) is added dropwise at -78 C. The reaction mixture is stirred for 30 min at -78 C. and then the reaction is allowed to warm to room temperature slowly and stirred over night at room temperature. To the reaction mixture 1 N HCl solution is added. The resulting mixture is extracted with EA and washed with sat. sodium chloride solution and water. The organic phase is dried over sodium sulfate, filtered and the solvent is evaporated in vacuo. The residue is purified by flash column chromatography (silica gel, PE/EA=8/2) to give the product.
To a solution of <strong>[60186-89-2]4-bromo-2,6-dimethoxy-pyrimidine</strong> (6.80 g, 27.94 mmol) in THF (190 mL) and diethylether (190 mL) n-butyllithium (in hexane/THF, 2.01 g, 30.74 mmol) is added dropwise with stirring at -78 C. After 4 min ethyl trifluoroacetate (4.46 g, 30.74 mmol) in THF (50 mL) is added dropwise at -78 C. The reaction mixture is stirred for 30 min at -78 C and then the reaction is allowed to warm to room temperature slowly and stirred over night at room temperature. To the reaction mixture 1 N HCI solution is added . The resulting mixture is extracted with EA and washed with sat. sodium chloride solution and water. The organic phase is dried over sodium sulfate, filtered and the solvent is evaporated in vacuo. The residue is purified by flash col umn chromatography (silica gel, PE / EA = 8 12) to give the product. MS (ESI+): m/z = 255 [M+H]+ TLC (silica gel, PE/EA 3/1 ): Rf = 0.20
  • 53
  • (R)-5-(1-hydroxy-2-(2,8-diazaspiro[4.5]decan-8-yl)ethyl)-4-methylisobenzofuran-1(3H)-one [ No CAS ]
  • [ 60186-89-2 ]
  • (R)-5-(2-(2-(2,6-dimethoxypyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-8-yl)-1-hydroxyethyl)-4-methylisobenzofuran-1(3H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); XPhos; In 1,4-dioxane; at 100℃;Sealed tube; To a microwave vial was charged (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (40 mg, 0.121 mmol) , 4-bromo-2, 6-dimethoxypyrimidine (26.5 mg, 0.121 mmol) , tris (dibenzylideneacetone) dipalladium (0) (5.54 mg, 6.05 mumol) , 2-dicyclohexylphosphino-2?, 4?, 6?-triisopropylbiphenyl (11.5 mg, 0.024 mmol) , and potassium phosphate (51.4 mg, 0.242 mmol) . The vial was sealed, degased, and filled with dioxane (0.60 mL) . The reaction mixture was heated at 100 overnight, diluted with water, extracted with EtOAc. The organic layer was washed with brined, dried, evaporated to give the crude product, which was purified by silica gel column chromatography (0-10 MeOH/DCM) to afford (R) -5- (2- (2- (2, 6-dimethoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-8-yl) -1-hydroxyethyl) -4-methylisobenzofuran-1 (3H) -one. LC-MS (ESI, m/z) : 469 [M+1] +.
  • 54
  • [ 67-56-1 ]
  • [ 36847-11-7 ]
  • [ 60186-89-2 ]
YieldReaction ConditionsOperation in experiment
23 g With sodium methylate; In diethyl ether; at 20℃; for 2h; Into a 2-L 3-necked round-bottom flask, was placed 2,4,6-tribromopyrimidine (54 g, 170.47 mmol, 1 equiv), methanol (500 mL), diethyl ether (500 mL), and MeONa/MeOH (30%) (76.7 g, 2.50 equiv) was added dropwise. The resulting solution was stirred for 2 h at RT. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 1 L of EA. The resulting mixture was washed with 3x500 mL of brine. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 : 100-1 : 10). The collected fractions were combined and concentrated under vacuum. This resulted in 23 g (62%) of the title compound as a white solid. Analytical Data: LC-MS: (ES, m/z): RT = 1.287 min, LCMS 28: m/z = 219 [M+l].
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 60186-89-2 ]

Bromides

Chemical Structure| 959240-72-3

A821227 [959240-72-3]

4-Bromo-2-methoxypyrimidine

Similarity: 0.83

Chemical Structure| 1086382-38-8

A215406 [1086382-38-8]

4-Bromo-6-hydroxypyrimidine

Similarity: 0.76

Chemical Structure| 944709-74-4

A229613 [944709-74-4]

2-Bromo-6-methoxypyrimidine

Similarity: 0.70

Chemical Structure| 19752-61-5

A143634 [19752-61-5]

5-Bromo-2,4-di-tert-butoxypyrimidine

Similarity: 0.66

Chemical Structure| 14001-66-2

A116042 [14001-66-2]

5-Bromo-2-methoxypyrimidine

Similarity: 0.65

Ethers

Chemical Structure| 3551-55-1

A206714 [3551-55-1]

2,4-Dimethoxypyrimidine

Similarity: 0.83

Chemical Structure| 959240-72-3

A821227 [959240-72-3]

4-Bromo-2-methoxypyrimidine

Similarity: 0.83

Chemical Structure| 186435-66-5

A134719 [186435-66-5]

6-Amino-2-methoxypyrimidin-4-ol

Similarity: 0.72

Chemical Structure| 120129-83-1

A249253 [120129-83-1]

2,4-Dimethoxy-5,6-dimethylpyrimidine

Similarity: 0.71

Chemical Structure| 6320-15-6

A963559 [6320-15-6]

4-Chloro-2,6-dimethoxypyrimidine

Similarity: 0.71

Related Parent Nucleus of
[ 60186-89-2 ]

Pyrimidines

Chemical Structure| 3551-55-1

A206714 [3551-55-1]

2,4-Dimethoxypyrimidine

Similarity: 0.83

Chemical Structure| 959240-72-3

A821227 [959240-72-3]

4-Bromo-2-methoxypyrimidine

Similarity: 0.83

Chemical Structure| 1086382-38-8

A215406 [1086382-38-8]

4-Bromo-6-hydroxypyrimidine

Similarity: 0.76

Chemical Structure| 186435-66-5

A134719 [186435-66-5]

6-Amino-2-methoxypyrimidin-4-ol

Similarity: 0.72

Chemical Structure| 6320-15-6

A963559 [6320-15-6]

4-Chloro-2,6-dimethoxypyrimidine

Similarity: 0.71